Presentation and outcome of hepatocellular carcinoma in HIV-infected patients:: A US-Canadian multicenter study

被引:182
作者
Braeu, Norbert [1 ]
Fox, Rena K.
Xiao, Peiying
Marks, Kristen
Naqvi, Zeenat
Taylor, Lynn E.
Trikha, Anita
Sherman, Morris
Sulkowski, Mark S.
Dieterich, Douglas T.
Rigsby, Michael O.
Wright, Teresa L.
Hernandez, Maria D.
Jain, Mamta K.
Khatri, Gajendra K.
Sterling, Richard K.
Bonacini, Maurizio
Martyn, Catherine A.
Aytaman, Ayse
Llovet, Josep M.
Brown, Sheldon T.
Bini, Edmund J.
机构
[1] Mt Sinai Sch Med, Bronx Vet Affairs Med Ctr, Div Infect Dis & Liver Dis, New York, NY 10029 USA
[2] Mt Sinai Sch Med, Div Infect Dis, New York, NY USA
[3] Mt Sinai Sch Med, Div Liver Dis, New York, NY USA
[4] Univ Calif San Francisco, VA Med Ctr, Sch Med, San Francisco, CA USA
[5] Cornell Univ, Presbyterian Hosp, Weill Coll Med, New York, NY USA
[6] Miriam Hosp, Brown Med Sch, Providence, RI 02906 USA
[7] Univ Turin, Toronto Gen Hosp, Sch Med, Toronto, ON, Canada
[8] Johns Hopkins Sch Med, Baltimore, MD USA
[9] Yale Univ, VA Med Ctr, Sch Med, New Haven, CT USA
[10] Univ Texas, SW Med Ctr, Dallas, TX USA
[11] VA Med Ctr, Salisbury, NC USA
[12] Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA
[13] Calif Pacific Med Ctr, San Francisco, CA USA
[14] SUNY Downstate Hlth Sci Ctr, VA New York Harbor Hlth Care Syst, Brooklyn, NY USA
[15] NYU, Sch Med, VA New York Harbor Hlth Care Syst, New York, NY USA
关键词
hepatocellular carcinoma; HIV; hepatitis C; hepatitis B; treatment;
D O I
10.1016/j.jhep.2007.06.010
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: HIV-infected patients now live longer and often have complications of liver disease, especially with hepatitis B or C virus coinfection. Limited data are available on those with hepatocellular carcinoma (HCC). Methods:A retrospective analysis from 1992 to 2005 in 6 centers identified 63 HIV-infected HCC patients. Controls were 226 consecutive HIV-negative HCC patients from four sites. Results: HIV-positive patients were younger than controls (52 vs. 64 years, p < 0.001), more commonly had chronic hepatitis B or C (97% vs. 73%, p < 0.001), were more frequently symptomatic (51% vs. 38%, p = 0.048), had a higher median alfa-fetoprotein level (227 vs. 51 ng/ml, p = 0.005), but a similar mean Child-Turcotte-Pugh score (7.0 vs. 7.5, p = 0.05) and HCC staging score (Barcelona-Clinic-Liver-Cancer stages C + D in 50% vs. 58%, p = 0.24). HCC developed faster in HIV/HCV-coinfected than in HCV-monoinfected patients (mean, 26 vs. 34 years after HCV infection, p = 0.002). HIV-positive patients received proven therapy more often (48% vs. 31%, p = 0.017), but median survival was similar (6.9 vs. 7.5 months, p = 0.44). Independent factors predicting survival were symptomatic presentation (hazard ratio [HR], 0.437; p < 0.001), any proven therapy (HR, 2.19; p < 0.001), diagnosis after 01-Jan-2002 (HR, 1.52; p = 0.010), Barcelona-Clinic-Liver-Cancer stages C + D (HR, 0.491; p < 0.001), AST/ALT >= 2.00 (HR, 0.597; p = 0.001), AFP >= 400 ng/mL (HR, 0.55, p = 0.003), and platelets >= 100,000/mm(3) (HR, 0.651; p = 0.012), but not HIV-serostatus (p = 0.19). In HIV-infected patients without HCC therapy (n = 33), median survival was longer with undetectable HIV RNA (<400 copies/mL) than with HIV viremia (6.5 vs. 2.6 months, p = 0.013). Conclusions: HIV-positive HCC patients are younger and more frequently symptomatic and infected with HCV or HBV than HIV-negative patients. Tumor staging and survival are similar. In untreated patients, undetectable HIV RNA independently predicts better survival. (C) 2007 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:527 / 537
页数:11
相关论文
共 38 条
[1]   Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients [J].
Benhamou, Y ;
Bochet, M ;
Di Martino, V ;
Charlotte, F ;
Azria, F ;
Coutellier, A ;
Vidaud, M ;
Bricaire, F ;
Opolon, P ;
Katlama, C ;
Poynard, T .
HEPATOLOGY, 1999, 30 (04) :1054-1058
[2]   Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection [J].
Bica, I ;
McGovern, B ;
Dhar, R ;
Stone, D ;
McGowan, K ;
Scheib, R ;
Snydman, DR .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (03) :492-497
[3]   Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy [J].
Bräu, N ;
Salvatore, M ;
Ríos-Bedoya, CF ;
Fernández-Carbia, A ;
Paronetto, F ;
Rodríguez-Orengo, JF ;
Rodríguez-Torres, M .
JOURNAL OF HEPATOLOGY, 2006, 44 (01) :47-55
[4]   Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[5]   Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French departments of internal medicine/infectious diseases, in 1995 and 1997 [J].
Cacoub, P ;
Geffray, L ;
Rosenthal, E ;
Perronne, C ;
Veyssier, P ;
Raguin, G .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (08) :1207-1214
[6]   A new prognostic classification for predicting survival in patients with hepatocellular carcinoma [J].
Chevret, S ;
Trinchet, JC ;
Mathieu, D ;
Rached, AA ;
Beaugrand, M ;
Chastang, C .
JOURNAL OF HEPATOLOGY, 1999, 31 (01) :133-141
[7]   Prospective validation of the Barcelona Clinic Liver Cancer staging system [J].
Cillo, U ;
Vitale, A ;
Grigoletto, F ;
Farinati, F ;
Brolese, A ;
Zanus, G ;
Neri, D ;
Boccagni, P ;
Srsen, N ;
D'Amico, F ;
Ciarleglio, FA ;
Bridda, A ;
D'Amico, DF .
JOURNAL OF HEPATOLOGY, 2006, 44 (04) :723-731
[8]  
COX DR, 1972, J R STAT SOC B, V34, P187
[9]   Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C [J].
Darby, SC ;
Ewart, DW ;
Giangrande, PLF ;
Spooner, RJD ;
Rizza, CR ;
Dusheiko, GM ;
Lee, CA ;
Ludlam, CA ;
Preston, FE .
LANCET, 1997, 350 (9089) :1425-1431
[10]  
EL SH, 1999, NEW ENGL J MED, V340, P745